Home » Stocks » Oncolytics Biotech

Oncolytics Biotech Inc. (ONCY)

Stock Price: $2.29 USD 0.04 (1.78%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $2.30 +0.01 (0.44%) Oct 23, 7:51 PM

Stock Price Chart

Key Info

Market Cap 95.39M
Revenue (ttm) n/a
Net Income (ttm) -33.12M
Shares Out 41.66M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $2.29
Previous Close $2.25
Change ($) 0.04
Change (%) 1.78%
Day's Open 2.29
Day's Range 2.20 - 2.31
Day's Volume 406,467
52-Week Range 0.47 - 6.02

More Stats

Market Cap 95.39M
Enterprise Value 81.75M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 41.66M
Float 41.00M
EPS (basic) -1.50
EPS (diluted) -0.83
FCF / Share -0.90
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.95M
Short Ratio 7.03
Short % of Float 4.75%
Beta 1.54
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.13
Revenue n/a
Operating Income -20.69M
Net Income -33.12M
Free Cash Flow -19.92M
Net Cash 13.64M
Net Cash / Share 0.33
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -54.38%
ROE -211.38%
ROIC 779.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$6.84*
(198.69% upside)
Low
4.53
Current: $2.29
High
9.00
Target: 6.84
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-20.69-16.66-15.61-15.29-13.92-18.82-23.90-36.69-28.72-19.89
Net Income-33.12-17.04-15.62-15.14-13.72-18.62-23.53-36.37-29.04-24.66
Shares Outstanding22.1416.0213.9412.6211.859.258.798.017.466.58
Earnings Per Share-1.50-1.06-1.12-1.20-1.14-2.00-2.66-4.56-3.90-3.71
Operating Cash Flow-19.91-11.92-14.89-12.48-15.03-19.68-24.44-34.26-22.54-17.88
Capital Expenditures-0.01-0.11-0.11-0.02-0.11-0.15-0.25-0.13-0.26-0.08
Free Cash Flow-19.92-12.03-15.00-12.50-15.14-19.83-24.70-34.38-22.80-17.96
Cash & Equivalents14.1513.7011.8414.1226.0816.1827.2221.2934.8642.91
Total Debt0.51---------
Net Cash / Debt13.6413.7011.8414.1226.0816.1827.2221.2934.8642.91
Assets19.6614.8718.1514.7627.3817.1928.2222.0836.0244.43
Liabilities19.778.679.874.072.713.376.017.296.508.04
Book Value-0.116.208.2810.6924.6713.8222.2114.7929.5236.39
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Oncolytics Biotech Inc.
Country Canada
CEO Matthew C. Coffey

Stock Information

Ticker Symbol ONCY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ONCY
IPO Date November 8, 1999

Description

Oncolytics Biotech, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.